Background {#Sec1}
==========

*Mycoplasma pneumoniae* (*M. pneumoniae*) is one of the major pathogens causing community acquired pneumonia and bronchitis in children. Treatment of *M. pneumoniae*-related respiratory infection is based on symptomatic treatment with antibiotics. Macrolides have been used as first line treatment. However, macrolide-refractory *M. pneumoniae* (MRMP) strains are increasing abruptly, particularly in East Asian countries including Korea, Japan, and China \[[@CR1]--[@CR3]\].

Most patients with MRMP do not show improvement of fever when they are treated with macrolides. Some may develop refractory or severe clinical course that requires additional treatment. Treatment for MRMP includes tetracyclines, fluoroquinolones, and systemic glucocorticoids \[[@CR4]\].

Secondary antibiotics such as tetracyclines and fluoroquinolones are considered as effective alternatives in the treatment of MRMP. However, they are of limited use due to safety-concerns of teeth discoloration and musculoskeletal toxicity, particularly in children. Glucocorticoids can be also considered as alternative treatment options due to two reason. First, the pathogenesis of *M. pneumoniae* infection is associated with amplified host immune response and virulence of *M. pneumoniae* \[[@CR5]\]. Second, adverse effects of glucocorticoids have been well established. Further risk is not likely to be added in the treatment of MRMP. However, previous studies on the effect of glucocorticoids have shown conflicting results \[[@CR6]--[@CR8]\].

The objective of this study was to assess the efficacy of glucocorticoids for treatment of MRMP in children through systematic review and meta-analysis.

Methods {#Sec2}
=======

Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 were used for this systematic review and meta-analysis \[[@CR9]\]. The Population-Intervention-Comparison-Outcome (PICO) question used for our search strategy was: "Does use of glucocorticoids help improve the outcome of MRMP in children?"

Search strategy {#Sec3}
---------------

We performed a systematic search utilizing a protocol designed by two independent medical librarians (D.W.S. and M.L) specifically for this study with 10 electronic databases: PubMed, EMBASE, Cochrane Library, and Core journal (Korean, Japanese, and Chinese Journal) Full-text Database. The search encompassed articles published from January, 1990 to March 8, 2018. We used search terms listed in Additional file [1](#MOESM1){ref-type="media"} to search PubMed, Cochrane, EMBASE, and database of core countries. We imposed no language or publication restrictions.

The first screening was executed by two independent reviewers (H.S.K. and I.S.S.) who evaluated the titles and abstracts obtained from the search. Records were managed using Endnote (version X8; Clarivate Analytics, Philadelphia, PA, USA). From this initial screening, articles that did not focus on glucocorticoid use in MRMP and review articles were immediately excluded. After initial exclusion process, full texts of the remaining articles were reviewed independently by two authors (H.S.K. and I.S.S.) to determine whether any articles met the predetermined eligibility criteria described in the next section. Disagreements between the two reviewers regarding the inclusion or exclusion of particular studies were settled by consultation with a third reviewer (Y.J.L.).

Eligibility {#Sec4}
-----------

The following inclusion criteria were applied: (1) randomized control trial (RCT) which compare the efficacy of glucocorticoids add-on to macrolide alone in children with MRMP, (2) MRMP which was diagnosed with serology or polymerase chain reaction, and that refractories were defined clinically, (3) only included children \< 18 years of age, and (4) outcome measures with hospital days, fever duration, and level of C-reactive protein (CRP) change. Review articles, published abstracts without full-text publications, and case-study reports with 10 participants or less were excluded. Our search strategy included non-English articles in our initial search results. Non-English articles were then translated and included for evaluation.

Study selection {#Sec5}
---------------

Two reviewers (H.S.K. and I.S.S.) independently screened titles and abstracts of the studies identified in our systematic search. Studies focusing on MRMP were included after review of abstracts. Full texts from included studies were reviewed to evaluate for eligibility. Reference lists of selected studies and previous reviews were also examined to determine any relevant publications overlooked by the electronic search. Disagreements between the two reviewers in the selection of particular studies were settled after discussion with a third reviewer (Y.J.L.).

Risk of bias assessment {#Sec6}
-----------------------

Cochrane Collaboration Risk of Bias Tool was used by the two reviewers (H.S.K. and I.S.S.) who independently evaluated the risk of bias in included studies \[[@CR10]\]. Risk of bias was determined as hi, low or unclear by evaluating random sequence generation, blinding of participants and personnel, incomplete outcome data, and selective reporting. Disagreements between the two reviewers regarding the risk of bias assessment of particular studies were settled after discussion with a third reviewer (Y.J.L.).

Data extraction {#Sec7}
---------------

Two reviewers (H.S.K. and I.S.S.) used a structured form to extract data from each eligible study. Data extracted from each study could be characterized as characteristics of the sample, intervention details, and measurement of outcomes. Disagreements between the two reviewers regarding the data extraction of particular studies were settled by consultation with a third reviewer (Y.J.L.). Primary outcomes of the current study were hospital days, fever duration, and change in CRP.

Statistical analysis {#Sec8}
--------------------

The estimated mean effect of glucocorticoid add-on treatment on hospital days, fever duration, and change in C-reactive protein (CRP) and the associated 95% confidence intervals (CIs) were extracted or calculated for the 24 studies included in the meta-analysis with Review Manager 5.3 (The Cochrane Collaboration, London, United Kingdom). Random-effects model was used for studies included in the analysis.

Heterogeneity was calculated using I^2^ statistic. The I^2^ statistic threshold should always be interpreted with care. A rough estimate of 25% denotes low heterogeneity while 50% denotes moderate heterogeneity, and 75% denotes high heterogeneity \[[@CR11]\]. We conducted sensitivity analyses when heterogeneity was noted. This was performed by removing a study from the analysis to determine changes in I^2^ values and assess which studies play a significant role resulting in heterogeneity \[[@CR11]\]. To assess the risk of publication bias, we used funnel plots for visual inspection, and Egger test and trim-and-fill method were performed for statistical identifying. All statistical analyses were performed using R (version 3·3·3) and Review Manager 5.3.

Results {#Sec9}
=======

Systematic literature search results {#Sec10}
------------------------------------

A total of 1829 citations were identified initially. Of these, 1773 studies were discarded after reviewing titles and abstracts, leaving 56 articles for full text review (Fig. [1](#Fig1){ref-type="fig"}). A total of 32 studies were excluded after full text review due to no proper subject, inadequate study protocol, review article, or no relevant outcome. A total of 24 studies were included in our systematic review and meta-analysis \[[@CR12]--[@CR35]\]. All studies were RCTs. (Additional file [1](#MOESM1){ref-type="media"} for search strategies for database, Additional file [2](#MOESM2){ref-type="media"} for PRISMA checklist). Fig. 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart

Sample characteristics {#Sec11}
----------------------

Participants of studies enrolled in our meta-analysis was a total of 2365 patients. All these studies examined fever duration. Fifteen studies examined hospital days while 14 studies examined CRP level after treatment (Table [1](#Tab1){ref-type="table"}). Table 1Characteristics of studies included in the meta-analysisStudyCharacteristicsInterventionOutcomeCountryYearNumber of subjects; mean age of experiment group, yNumber of subjects; mean age of control groupExperimental groupControl groupFan Xuwei 2015 \[[@CR18]\]China2012--201544; 8.2 ± 2.743; 7.2 ± 2.1MPD (2 mg/kg/d) for 5 consecutive days then received 1 mg/kg/d for 2 daysOral administration of AZM tablets (10 mg/kg; max. dose 0.5 g) for 1 day then received 5 mg/kg of AZM through day 2--5 (max. dose 0.25 g)Fever duration, Hospital day, CRP changeFeng Xiaoqiang 2016 \[[@CR26]\]China2013--2015Fever duration, Hospital day, Cough duration, Improvement of chest x-rayJi Chaoyu 2017 \[[@CR28]\]China2014--201650; 5.1 ± 0.350; 4.9 ± 0.5IV MPD (2 mg/kg/d) for 3 daysDaily IV infusion of AZM (10 mg/kg/d)Fever duration, Cough durationLi Ling 2015 \[[@CR14]\]China2013--201453; 6.5 ± 2.151; 6.6 ± 1.9MPD (2 mg/kg/d) for 3--5 daysErythromycin IV drip for 1 week, then change to AZM IV drip for 3 days, stop for 4 days, then oral AZM tablets for 3 days, then stop for 4 days then oral AZM tablets for 3 days again, with 3rd generation cephalosporinFever duration, Hospital days, Cough duration, Change in chest x-ray, CRP changeLi Ming 2015 \[[@CR15]\]China2013--201450; 3.1 ± 0.450; 3.2 ± 0.2IV administration of prednisolone sodium succinate 1--2 mg/kg/d for 3 days, then changed to oral administration of prednisone 1--2 mg/kg/d, then stopped 7--10 days of taperingDaily IV administration of AZM (10 mg/kg/d) for 3--5 days, then stopped for 3 days. Sequential therapy with daily administration of AZM dry suspension 10 mg/kg/d for 3 days then stopped for 4 days, and repeated for total course of treatment of 1 monthFever duration, Hospital days, Cough duration, CRP changeLin Jianqin 2015 \[[@CR16]\]China2012--201542; 6.4 ± 1.241; 6.1 ± 1.3IV MPD 1 mg/kg/time, 2 times/day, for 3 days, then changed to oral administration of MPD, 1 mg/kg/time, 2 times/dayDaily IV AZM 10 mg/kg, for 3--5 days then oral administration of AZM 10 mg/kg/d for 3 days then stop for 4 days. Oral administration was repeated for 2--3 times during course of treatmentFever duration, Cough duration, Time to normalization of chest x-rayLin Yan 2015 \[[@CR17]\]China2012--201545; 6.4 ± 3.245; 6.7 ± 3.3IV infusion of dexamethasone 0.2--0.3 mg/kg/d for 5 daysIV infusion of AZM and gamma globulinFever duration, Hospital day, Cough duration, Time to normalization of chest x-ray, CRP changeLiu Chunyan 2017China2015--201652; 5.8 ± 4.052; 5.6 ± 4.2IV MPD pulse therapy (1--2 mg/kg/d) for 3 daysIV infusion of immunoglobulin 400 mg/kg/d for 2 days; IV infusion of AZM 10 mg/kg/d for 5 daysFever duration, Time to normalization of chest x-rayLiu Qing 2016 \[[@CR22]\]China2013--201574;62;IV infusion of MPD 2 mg/kg/d was administered until 24 h after defervescence. Oral prednisone was started with 1--2 mg/kg/d then tapered for 7--14 daysIV infusion of AZM 10 mg/kg/d for 5 days then stop 4 days and repeat for 2--3 cyclesFever durationLu Xiaoyun 2017 \[[@CR29]\]China2014--201553; 6.59 ± 1.5752; 6.80 ± 1.43IV infusion of MPD 2 mg/kg/d for 5 days10 mg/kg of oral AZM for 1 day continued by 5 mg/kg of AZM from day 2--5.Fever duration, Cough duration, Time to normalization of chest x-ray, CRP changeQiu Haiyan 2017China2015--201650; 6.91 ± 2.1650; 6.85 ± 2.10MPD 1--2 mg/kg/dIV AZM (10 mg/kg/d) was used until symptom improvement then changed to daily oral AZM suspension 10 mg/kg/dFever duration, Cough duration, CRP changeRen Mingxing 2015China2011--201333; 8.9 ± 2.434; 9.3 ± 3.0MPD 2 mg/kg/d for 5 days then reduced to 1 mg/kg/d for 2 daysIV infusion of aspartate AZM 10 mg/kg/d for 3 days; daily IV infusion of gamma globulin 1.5 g/kg for 3 days; IV infusion of rifampicin 10 mg/kg/d for 3 days then stopped for 4 days then change to oral administration of AZM 10 mg/kg/d for 3 days then stopped for 4 days. Total duration of treatment was 7 days for one course of treatment and was continued for 3 weeksFever duration, Hospital days, CRP changeShan Li-Shen 2017 \[[@CR35]\]China2013--201552; 7.36 ± 2.3350; 7.29 ± 3.03Oral or IV MPD 2 mg/kg/d for 3 daysIV AZMFever duration, CRP change, LDH change, D-dimer changeShao Xiaoli 2011 \[[@CR12]\]China2008--201038; 6.37 ± 2.8338; 6.87 ± 2.86Small dose of MPD for 3--4 weeksMacrolide antibioticsFever duration, Hospital days, Cough duration, Chest X-ray changeTao Xuyun 2015China2013--201475; 7.4 ± 1.475; 7.3 ± 1.3IV MPD 2 mg/kg/d for 4--5 days then on 5--7 day of treatment, dose increased to 4 mg/kg/d according to patient symptoms. Then reduced to 1 mg/kg/d for 3 days after defervescence.IV AZM (10 mg/kg/d) for 3 days then stopped for 4 days. Followed by oral AZM for 3 days then stopped for 4 days continued for 3 weeks with ceftazidimeFever duration, Hospital day, Cough duration, Change in chest X-ray, CRP changeWang Hao 2016 \[[@CR24]\]China2013--201540; 5.10 ± 1.8640; 4.86 ± 1.354 consecutive days with 2 mg/kg/d of MPD then reduced to 1 mg/kg/dDaily IV infusion of AZM 10 mg/kg/d for 3 days. Then changed to 5 mg/kg/d of oral AZM, 3 times/day, for 3 days then stopped for 4 daysFever duration, Hospital day, CRP changeWen Jianjun 2016 \[[@CR23]\]China65; 7.1 ± 4.565; 7.7 ± 4.5IV infusion of MPD (2 mg/d, 1--2 times) and reduced as symptoms improvedIV AZM 10 mg/kg/d for 3 days then stopped for 4 days. Changed to oral AZM after symptoms improveFever duration, Hospital daysWu Yourong 2017 \[[@CR33]\]China2013--2014MPD 2 mg/kg/d for 3 days. Then changed to 1 mg/kg/d for 2 daysIV infusion of AZM 10 mg/kg/d for 3 days. After 3 consecutive days of treatment, oral AZM (10 mg/kg/d) was administered for 3 days then stopped for 4 daysFever duration, Hospital daysXu Jiali 2017China2015--201760; 6.8 ± 1.660; 7.1 ± 2.5Oral intake of MPD (2 mg/kg/d) for 3--5 days on 2nd day of treatmentDaily oral intake of AZM 10 mg/kg/d for 3 days then stopped for 4 days then repeated for 3--4 timesFever duration, Hospital days, Cough duration, CRP changeYang Lijun 2015 \[[@CR19]\]China2012--20142020IV administration of MPD (1 mg/kg/d) for 2 weeksIV infusion of AZM (7--10 mg/kg/d)Fever duration, Hospital days, Cough durationYu Jieming 2017 \[[@CR32]\]China2014--201535; 5.6 ± 2.735; 5.7 ± 2.3IV infusion of MPD (2 mg/kg/d), 2 times/day.IV infusion of erythromycin 20--30 mg/kg/d, 2 times/d. Change to oral AZM (10 mg/kg/d) after 48 h of defervescenceFever duration, Cough duration, CRP changeZhang Xiang 2015 \[[@CR21]\]China2012--201332; 5 ± 232; 4 ± 1IV infusion of MPD (1--2 mg/kg/d) with nebulized budesonide, for 3--5 days; If symptoms don't improve, oral administration of MPD was given for 3--5 days.IV infusion of erythromycin 20--30 mg/kg/d, for 2 times/day, for 7 days; followed by oral administration of AZM 10 mg/kg/d (max. dose 0.5 g/d), for 3 days then stopped for 4 daysFever duration, Hospital daysZhao Shuqing 2017 \[[@CR34]\]China2013--201529; 5.7 ± 2.429; 5.3 ± 2.5Daily IV MPD 1.5--2.0 mg/kg/d for 3 days, then changed to 1 mg/kg/d and tapering within 1 weekIV AZM 10 mg/kg/d on the 1st day, 5 mg/kg/d from 2nd to 5th day, 5 days as a total treatment courseFever duration, Cough duration, CRP changeZheng Xuan 2016 \[[@CR25]\]China2015--201670; 5.5 ± 0.570; 5.1 ± 0.6IV infusion of MPD (2 mg/kg/d) for 3 daysIV infusion of AZM (10 mg/kg/d) for 3 daysFever duration, Cough duration, CRP change*Abbreviations*: *AZM* azithromycin, *CRP* C-reactive protein, *IV* intravenous, *LDH* lactate dehydrogenase, *MPD* methylprednisolone

Fever duration {#Sec12}
--------------

The mean length of total duration of fever was significantly shorter in the glucocorticoid add-on group than that in the conventional treatment group (weighted mean difference, WMD = − 3.32, 95%CI: − 4.16 -- -2.48, Z = 7.72, *P* \< 0.00001). However, there was a high between-study heterogeneity of this effect (I^2^ = 98%; Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Comparison of fever duration between glucocorticoid therapy and macrolide therapy

Hospital days {#Sec13}
-------------

The mean length of hospital stays in the glucocorticoid add-on treatment group was significantly shorter than that in the conventional treatment group (WMD = − 4.03, 95% CI: − 4.89 - -3.18, Z = 9.26, *P* \< 0.00001). However, there was a high between-study heterogeneity of this effect (I^2^ = 90%; Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Comparison of hospital days between glucocorticoid therapy and macrolide therapy

Reduction of CRP level after treatment {#Sec14}
--------------------------------------

The level of CRP after treatment was significantly lower in the glucocorticoid add-on treatment group than that in the conventional treatment group (WMD = − 16.03, 95%CI: − 22.56 -- -9.50, Z = 4.81, *P* \< 0.00001). However, there was a high between-study heterogeneity of this effect (I^2^ = 100%; Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Comparison of C-reactive protein level after treatment between glucocorticoid therapy and macrolide therapy

Sensitivity analyses was performed because of high level of heterogeneity. We removed a study from the analysis to determine which studies contributed most significantly to the heterogeneity by determining the changes in I^2^ values. We found that I^2^ values of fever duration, hospital days, and CRP level did not change.

Subgroup analysis {#Sec15}
-----------------

Use of glucocorticoids included the use of any type of glucocorticoids (e.g., methylprednisolone, dexamethasone, and prednisolone). The use of different types of glucocorticoids was different across studies. This might have contributed to the heterogeneity in the overall use of glucocorticoids. Thus, we stratified the meta-analysis by subgroup analyses. In subgroup meta-analysis for use of methylprednisolone compared with the use of other glucocorticoids for the length of hospital stay, the use of other steroids did not show any significant subgroup differences (Figs. [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}). Fig. 5Forest plot for hospital days in subgroup analysis with use of methylprednisolone and other steroids Fig. 6Forest plot for fever duration in subgroup analysis with use of methylprednisolone and other steroids Fig. 7Forest plot for C-reactive protein level in subgroup analysis with use of methylprednisolone and other steroids

Publication bias {#Sec16}
----------------

All funnel plots were symmetric, indicating an absence of significant publication bias within these studies except for CRP outcome. Egger test results were − 1.73 (*P* = 0.09) for fever duration, 0.59 (*P* = 0.56) for hospital days, and − 3.19 (*P* = 0.008) for CRP. Trim-and-fill method for adjusting publication bias on CRP outcome was performed. The mean difference changed from -- 3.27 (*P* = 0.35) to − 16.03 (*P* \< 0.001). These results indicated that there was substantial evidence of publication bias in CRP outcome (Fig. [8](#Fig8){ref-type="fig"}). Fig. 8Funnel plots showing WMDs and 95% CIs for the efficacy of glucocorticoid therapy on the length of hospital stays (**a**), fever duration (**b**), and level of change of C reactive protein (**c**). Tests of asymmetry showed no significant deviation from the symmetry assumption (**a**, *P* = 0.56; **b**, *P* = 0.06). However, significant asymmetry was found in the level of change of CRP (**c**, *P* = 0.008). Trim-and-fill method for adjusting publication bias was used. Results showed substantial evidence of publication bias in CRP outcome (**d**)

Discussion {#Sec17}
==========

This systematic review and meta-analysis identified and assessed RCTs on the use of glucocorticoids in children with MRMP. We specifically investigated effects of glucocorticoids on fever duration, length of hospital stay, and CRP level after treatment in comparison with conventional macrolide therapy. Results revealed positive effects of glucocorticoid treatment on all outcome measures.

*M. pneumoniae* is a common pathogen causing community acquired pneumonia. The clinical course of *M. pneumoniae* infection is diverse, ranging from self-limiting to severe pneumonia with extra-pulmonary complications \[[@CR36]\]. Macrolide is considered the first-line treatment for *M. pneumoniae* infection \[[@CR37]\]. In adults, one study reported that prednisone treatment for 7 days in patients with community-acquired pneumonia admitted to hospital can shorten time to clinical stability without increase in complications \[[@CR38]\]. However, another study reported that glucocorticoid use did not show any benefits in children \[[@CR8]\]. Pulmonary injury associated with severe mycoplasma pneumonia could be caused by host immune response rather than by direct microbial damage \[[@CR39], [@CR40]\]. Overly active cell-mediated immunity and cytokine responses play a significant role in MRMP \[[@CR41]\]. Severe *M. pneumoniae* infections and MRMP show similar laboratory findings with severe acute respiratory syndrome such as increased levels of non-specific markers of inflammation such as serum CRP, lactate dehydrogenase, and D-dimer \[[@CR42]\]. Since MRMP can be considered as an immune-mediated disease, use of immune modulatory therapy could seem rational. For cases with MRMP infection, secondary treatment options are limited due to adverse effects of tetracycline or fluoroquinolones, especially in children \[[@CR43]\]. The use of systemic steroids, in addition to antimicrobial therapy, to diminish host immune response in MRMP has been used in children and demonstrated satisfactory effects \[[@CR7], [@CR8], [@CR14]\]. Glucocorticoids have shown to improve clinical features and reduce lung injury in children and adults \[[@CR5], [@CR44], [@CR45]\]. The use of glucocorticoids in *M. pneumoniae* infection showed reduced lung histopathologic score by reducing cytokines and decreasing inflammatory response ultimately leading to lower mortality \[[@CR5], [@CR44], [@CR45]\]. Therefore, glucocorticoids have been considered suitable as adjunctive therapy to macrolide therapy. Although previous studies have reported the efficacy of glucocorticoids in the treatment of severe MRMP, treatment protocols varied from oral prednisolone of 1 mg/kg/day to intravenous methylprednisolone 30 mg/kg/day for 3 days \[[@CR7], [@CR17]\]. These variable treatment protocols are due to the lack of guidelines for glucocorticoids treatment in severe MRMP to date \[[@CR7], [@CR46]\].

In our study, the mean length of total duration of fever, mean length of hospital stay, and level of CRP after treatment in the glucocorticoid treatment group were significantly shorter or lower than that those in the conventional treatment group. However, heterogeneity in all outcome measures was high and sensitivity analysis resulted in no significant difference. Subgroup analysis showed no significant decrease in heterogeneity. In spite of high level of heterogeneity, all studies reported favorable outcomes of hospital stays and fever duration after the use of glucocorticoids in MRMP. For CRP level, only one study reported unfavorable result after the use of glucocorticoids in MRMP. Therefore, we could consider that the use of glucocorticoids has significantly favorable effects on outcomes of MRMP.

The strength of this review is that it summarized the current evidence on the efficacy of glucocorticoids from RCT. Conducting RCTs offers the potential to produce the most definitive evidence to confirm or refute whether glucocorticoids can help improve outcomes of MRMP.

This review has some limitations. Firstly, almost all studies included in this review had at least one methodological flaw. Secondly, publication bias was significant for change in CRP level. It might be due to small sample sizes in most studies and the fact that most studies were conducted in a single country. As a result, the robustness of these outcomes should be explored with future studies. Thirdly, most of the studies included were from a single country. Lastly, we could not evaluate other outcomes such as improvement in chest x-ray infiltration or other symptoms such as cough because these data were not available in each study.

Despite these limitations, with our review and meta-analysis, this is the first study to date to synthesize the efficacy of glucocorticoids in MRMP.

Conclusions {#Sec18}
===========

In conclusion, even though some studies have reported the efficacy and effectiveness of systemic glucocorticoids in the treatment of MRMP \[[@CR12]--[@CR35]\], this is the first systematic review and meta-analysis to investigate the effectiveness of glucocorticoids in MRMP. We found that the use of glucocorticoids could shorten hospital days, shorten fever duration, and lower CRP levels after treatment.

However, these results should be interpreted cautiously, and future studies should also assess other outcomes to clarify the effect of glucocorticoids in MRMP.
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CI

:   Confidence interval

CRP

:   C-reactive protein

*M. pneumoniae*

:   *Mycoplasma pneumoniae*

MRMP

:   Macrolide-refractory *M. pneumoniae*

PICO

:   Population-Intervention-Comparison-Outcome

PRISMA-P

:   Systematic Review and Meta-Analysis Protocols

RCT

:   Randomized control trial

WMD

:   weighted mean difference
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